Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03225963
Recruitment Status : Unknown
Verified July 2017 by Taichung Veterans General Hospital.
Recruitment status was:  Recruiting
First Posted : July 21, 2017
Last Update Posted : July 24, 2017
Sponsor:
Information provided by (Responsible Party):
Taichung Veterans General Hospital

Tracking Information
First Submitted Date July 19, 2017
First Posted Date July 21, 2017
Last Update Posted Date July 24, 2017
Actual Study Start Date August 1, 2015
Estimated Primary Completion Date July 31, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: July 19, 2017)
Response of bevacizumab therapy. [ Time Frame: 3 months after bevacizumab therapy ]
Base on the image after bevacizumab therapy (after recurrence)
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT03225963 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.
Official Title Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.
Brief Summary Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.
Detailed Description Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
DNA of peripheral mononulcear cells.
Sampling Method Probability Sample
Study Population Obtain peripheral blood pre-chemotherapy, mid-chemoradition and post-chemoraidtion
Condition
  • Glioblastoma Multiforme
  • Angiogenesis
Intervention Radiation: Chemoradiation with temozolomide
Study Groups/Cohorts Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: July 19, 2017)
60
Original Estimated Enrollment Same as current
Estimated Study Completion Date July 31, 2018
Estimated Primary Completion Date July 31, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Age older than 20 year old.
  • Glioblastoma patients who will receive chemoradiation treatment.

Exclusion Criteria:

  • None
Sex/Gender
Sexes Eligible for Study: All
Ages 20 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Taiwan
Removed Location Countries  
 
Administrative Information
NCT Number NCT03225963
Other Study ID Numbers CE15180B
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Taichung Veterans General Hospital
Study Sponsor Taichung Veterans General Hospital
Collaborators Not Provided
Investigators
Study Chair: Weir Chiang You, M.D. Ph.D. The Institutional Review Board of Taichung Veterans General Hospital
PRS Account Taichung Veterans General Hospital
Verification Date July 2017